Bad to the Bone: Unlocking the Molecular Regulation of Osteoblast Differentiation and Bone Synthesis
by Stephen Rodda and Andy McMahon
The mammalian skeleton is important for many physiological functions; as a scaffold, it supports the body, enabling motion and mechanical loading, and it provides protection for the internal organs. The bones also provide a niche for postnatal hematopoiesis and are the central store for calcium. As such, any modulation in skeletal strength or integrity, such as that experienced through injury (e.g., fracture) or disease state (e.g., osteoporosis) can severely compromise the quality of life and survival of all vertebrates.
While there are several cell lineages contributing to the skeleton during development, each gives rise to a common bone-generating cell type, the osteoblast. Despite the commonality of this cell type to all bone formation, bone can be produced by two distinct mechanisms: direct differentiation from the mesenchymal progenitor (occurring in the skull and face, called intramembranous ossification) or the formation of bone on a cartilage scaffold (called endochondral ossification, used by the rest of the skeleton).
Endochondral ossification, the focus of our current study, is initiated by the condensation of multipotent mesenchymal progenitor cells into structures that anticipate elements of the adult skeleton. Chondrocytes are the first cell type to form, starting out as immature proliferative cells, which initiate the formation of the cartilage matrix, then differentiating to postmitotic hypertrophic chondrocytes. Osteoblast progenitor cells are first evident in the inner layer of perichondral cells, which lie adjacent to the zone of hypertrophic chondrocytes.
Several lines of evidence implicate Hedgehog (Hh) and canonical Wnt signaling in the regulation of endochondral ossification. Indian hedgehog (Ihh) is expressed by prehypertrophic chondrocytes and acts directly on perichondrial mesenchyme to initiate an osteogenic program. Several recent developmental studies have suggested that canonical Wnts play a role in specification of osteoblasts. Specifically, Cre recombinase expressed under the control of promoters that are active broadly during skeletal development have been used to conditionally inactivate b-catenin function, resulting in an overall failure to develop bone. Despite a common result, these studies disagreed with respect to where along the osteoblast lineage canonical Wnt signaling functions and whether it acts directly.
In this study, we used a broad acting Cre mouse line, Col2cre, to remove b-catenin function in both the chondrocyte lineage and osteoblast lineage, permitting the detailed characterization of where along the osteoblast lineage these cells arrest. While mutant embryos failed to produce terminally differentiated osteoblasts, they were able to produce osteoblast precursor cells that express Osx1, suggesting a role for canonical Wnt downstream of Osx1. To test this hypothesis we generated a novel Osx1-GFP::Cre mouse strain, where Cre expression is restricted to the osteoblast lineage. Using this mouse line to remove b-catenin function resulted in a phenotype consistent with the Col2cre removal of b-catenin function, demonstrating that canonical Wnt functions directly on the osteoblast lineage and downstream of Osx1 expression. Interestingly, cell fate analysis demonstrates that on removal of b-catenin activity, Osx1 expressing osteoblast precursors give rise to ectopic chondrocytes instead of osteoblasts. This suggests that, along with earlier reports, there is an extended role for canonical Wnt signaling in suppression of an alternate chondrocytic fate within osteoblast precursors. In contrast to loss-of-function studies, use of the Osx1-GFP::Cre line to enhance b-catenin activity rapidly accelerated this program, leading to a dramatic expansion of osteoblast precursors and the premature synthesis of a mineralized bone matrix in the long bones.
|
|
Fig. 1. Osx1-GFP::Cre removal of §-catenin function affects skeletal development. Skeletal preparations of §-cateninc/n (wild type) and Osx1-GFP::Cre;§-cateninc/n (mutant) embryos at E14.5, E16.5 and E18.5. Higher magnifications of the fore- and hindlimbs are presented below each embryo. White arrowheads indicate comparable levels of hypertrophy between wild-type and mutant tibia. Arrows indicate the absence of mineralized bone matrix in mutants when compared with wild-type embryos (black arrowheads).
|
Finally, using the Osx1-GFP::Cre line, we were able to conditionally block the ability of osteoblast precursors to respond to a Hh signal, demonstrating that once osteoblast progenitor cells reach an Osx1 state, Hh signaling is dispensable for the rest of terminal differentiation.
Overall, this study has defined the precise states of cell differentiation along the osteoblast lineage that Hh and canonical Wnt function, and importantly identified canonical Wnt as a key mediator in the regulation and onset of mineralized matrix production, both key aspects of bone homeostasis and fracture repair.
|
|
Fig. 2. Proposed model for the role of Hh and canonical Wnt signaling in regulating the differentiation of skeletal progenitors. Various lines of evidence implicate the importance of canonical Wnt signaling at multiple stages along the osteoblast differentiation pathway, from the specification of early skeletal progenitor cells to a terminally differentiated osteoblast. Observations from previous studies, together with results presented in this study, have been used to synthesize a working model for the specific functions of Hh and canonical Wnt signaling during osteoblast specification and differentiation. Red and green arrows indicate the requirement for Hh and canonical Wnt signaling, respectively; the blue line represents the negative regulation of osteoclasts by OPG.
|
Rodda SJ, McMahon AP. Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development. 2006 Aug;133(16):3231-44. Read Abstract.
- Melton DA. Reversal of type 1 diabetes in mice. N Engl J Med. 2006 Jul 6;355(1):89-90. Read Abstract.
- Chien KR. Lost and found: cardiac stem cell therapy revisited. J Clin Invest. 2006 Jul;116(7):1838-40. Read Abstract.
- Walters DK, Mercher T, Gu TL, O'hare T, Tyner JW, Loriaux M, Goss VL, Lee KA, Eide CA, Wong MJ, Stoffregen EP, McGreevey L, Nardone J, Moore SA, Crispino J, Boggon TJ, Heinrich MC, Deininger MW, Polakiewicz RD, Gilliland DG, Druker BJ. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell. 2006 Jul;10(1):65-75. Read Abstract.
- Swirski FK, Pittet MJ, Kircher MF, Aikawa E, Jaffer FA, Libby P, Weissleder R. Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease. Proc Natl Acad Sci USA. 2006 Jul 5;103(27):10340-5. Read Abstract.
- Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ, McClure RF, Litzow MR, Gilliland DG, Tefferi A. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006 Jul 25. Read Abstract.
- Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, Levine JE, Wang J, Hahn WC, Gilliland DG, Golub TR, Armstrong SA. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006 Jul 16. Read Abstract.
- Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, Deangelo DJ, Clark JJ, Lee SJ, Golub TR, Wadleigh M, Gilliland DG, Levine RL. MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia. PLoS Med. 2006 Jul 18;3(7):e270 Read Abstract.
- Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, Klickstein LB, Levin J, Miller K, Reynolds C, Macdonell R, Pasek M, Lee SJ, Ho V, Soiffer R, Antin JH, Ritz J, Alyea E. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006 Jul 15;108(2):756-62. Read Abstract.
- Choi Y, Weissleder R, Tung CH. Selective antitumor effect of novel protease-mediated photodynamic agent. Cancer Res. 2006 Jul 15;66(14):7225-9. Read Abstract.
- Rocnik JL, Gilliland DG. Cell-autonomous and -nonautonomous contributions of STAT1 in murine models of tumorigenesis. Cancer Cell. 2006 Jul;10(1):1-2. Read Abstract.
- Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, Donahoe PK. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci USA. 2006 Jul 25;103(30):11154-9. Read Abstract.
- Morissette MR, Cook SA, Foo S, McKoy G, Ashida N, Novikov M, Scherrer-Crosbie M, Li L, Matsui T, Brooks G, Rosenzweig A. Myostatin regulates cardiomyocyte growth through modulation of Akt signaling. Circ Res. 2006 Jul 7;99(1):15-24. Read Abstract.
- Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ, Rosenzweig A, Salomon RN, Van Etten RA, Alroy J, Durand JB, Force T. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006 Jul 23. Read Abstract.
- Hataishi R, Rodrigues AC, Neilan TG, Morgan JG, Buys E, Shiva S, Tambouret R, Jassal DS, Raher MJ, Furutani E, Ichinose F, Gladwin MT, Rosenzweig A, Zapol WM, Picard MH, Bloch KD, Scherrer-Crosbie M. Inhaled nitric oxide decreases infarction size and improves left ventricular function in a murine model of myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2006 Jul;291(1):H379-84. Read Abstract.
- Cho SH, Cepko CL. Wnt2b/{beta}-catenin-mediated canonical Wnt signaling determines the peripheral fates of the chick eye. Development. 2006 Aug;133(16):3167-77. Read Abstract.
- Goishi K, Shimizu A, Najarro G, Watanabe S, Rogers R, Zon LI, Klagsbrun M. {alpha}A-crystallin expression prevents {gamma}-crystallin insolubility and cataract formation in the zebrafish cloche mutant lens. Development. 2006 Jul;133(13):2585-93. Read Abstract.
- Xu G, Kaneto H, Lopez-Avalos MD, Weir GC, Bonner-Weir S. GLP-1/exendin-4 facilitates beta-cell neogenesis in rat and human pancreatic ducts. Diabetes Res Clin Pract. 2006 Jul;73(1):107-10. Read Abstract.
- Galande AK, Hilderbrand SA, Weissleder R, Tung CH. Enzyme-targeted fluorescent imaging probes on a multiple antigenic Peptide core. J Med Chem. 2006 Jul 27;49(15):4715-20. Read Abstract.
- Montet X, Weissleder R, Josephson L. Imaging pancreatic cancer with a Peptide-nanoparticle conjugate targeted to normal pancreas. Bioconjug Chem. 2006 Jul-Aug;17(4):905-11. Read Abstract.
- Deguchi JO, Aikawa M, Tung CH, Aikawa E, Kim DE, Ntziachristos V, Weissleder R, Libby P. Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation. 2006 Jul 4;114(1):55-62. Read Abstract.
- Kelly KA, Nahrendorf M, Yu AM, Reynolds F, Weissleder R. In vivo phage display selection yields atherosclerotic plaque targeted peptides for imaging. Mol Imaging Biol. 2006 Jul-Aug;8(4):201-7. Read Abstract.
- Mempel TR, Pittet MJ, Khazaie K, Weninger W, Weissleder R, von Boehmer H, von Andrian UH. Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. Immunity. 2006 Jul;25(1):129-41. Read Abstract.
- Hyatt G, Melamed R, Park R, Seguritan R, Laplace C, Poirot L, Zucchelli S, Obst R, Matos M, Venanzi E, Goldrath A, Nguyen L, Luckey J, Yamagata T, Herman A, Jacobs J, Mathis D, Benoist C. Gene expression microarrays: glimpses of the immunological genome. Nat Immunol. 2006 Jul;7(7):686-91. Read Abstract.
- Wu Y, Borde M, Heissmeyer V, Feuerer M, Lapan AD, Stroud JC, Bates DL, Guo L, Han A, Ziegler SF, Mathis D, Benoist C, Chen L, Rao A. FOXP3 Controls Regulatory T Cell Function through Cooperation with NFAT. Cell. 2006 Jul 28;126(2):375-87. Read Abstract.
- Kim J, Kil IS, Seok YM, Yang ES, Kim DK, Lim DG, Park JW, Bonventre JV, Park KM. Orchiectomy Attenuates Post-ischemic Oxidative Stress and Ischemia/Reperfusion Injury in Mice: A ROLE FOR MANGANESE SUPEROXIDE DISMUTASE. J Biol Chem. 2006 Jul 21;281(29):20349-56. Read Abstract.
- Perez-Rojas J, Blanco JA, Cruz C, Trujillo J, Vaidya VS, Uribe N, Bonventre JV, Gamba G, Bobadilla NA. Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol. 2006 Jul 11. Read Abstract.
- Lin L, Isacson O. Axonal growth regulation of fetal and ES-derived dopaminergic neurons by Netrin-1 and Slits. Stem Cells. 2006 Jul 13. Read Abstract.
- Rajab A, Yoo SY, Abdulgalil A, Kathiri S, Ahmed R, Mochida GH, Bodell A, Barkovich AJ, Walsh CA. An autosomal recessive form of spastic cerebral palsy (CP) with microcephaly and mental retardation. Am J Med Genet A. 2006 Jul 15;140(14):1504-10. Read Abstract.
- Neal J, Apse K, Sahin M, Walsh CA, Sheen VL. Deletion of chromosome 1p36 is associated with periventricular nodular heterotopia. Am J Med Genet A. 2006 Jul 11. Read Abstract.
- Sun T, Collura RV, Ruvolo M, Walsh CA. Genomic and evolutionary analyses of asymmetrically expressed genes in human fetal left and right cerebral cortex. Cereb Cortex. 2006 Jul;16 Suppl 1:i18-25. Read Abstract.
- Rodda SJ, McMahon AP. Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development. 2006 Aug;133(16):3231-44. Read Abstract.
- Yuen CM, Rodda SJ, Vokes SA, McMahon AP, Liu DR. Control of transcription factor activity and osteoblast differentiation in Mammalian cells using an evolved small-molecule-dependent intein. J Am Chem Soc. 2006 Jul 12;128(27):8939-46. Read Abstract.
- Kuo WP, Liu F, Trimarchi J, Punzo C, Lombardi M, Sarang J, Whipple ME, Maysuria M, Serikawa K, Lee SY, McCrann D, Kang J, Shearstone JR, Burke J, Park DJ, Wang X, Rector TL, Ricciardi-Castagnoli P, Perrin S, Choi S, Bumgarner R, Kim JH, Short GF 3rd, Freeman MW, Seed B, Jensen R, Church GM, Hovig E, Cepko CL, Park P, Ohno-Machado L, Jenssen TK. A sequence-oriented comparison of gene expression measurements across different hybridization-based technologies. Nat Biotechnol. 2006 Jul;24(7):832-840. Read Abstract.
- Fuchs JR, Nasseri BA, Vacanti JP, Fauza DO. Postnatal myocardial augmentation with skeletal myoblast-based fetal tissue engineering. Surgery. 2006 Jul;140(1):100-7. Read Abstract.
- Bachrach E, Perez AL, Choi YH, Illigens BM, Jun SJ, del Nido P, McGowan FX, Li S, Flint A, Chamberlain J, Kunkel LM. Muscle engraftment of myogenic progenitor cells following intraarterial transplantation. Muscle Nerve. 2006 Jul;34(1):44-52. Read Abstract.
The Harvard Stem Cell Institute is a scientific collaborative established to fulfill the promise of stem cell biology as the basis for cures and treatments for a wide range of chronic medical conditions.
Visit our website at www.hsci.harvard.edu
If there is anything that you would like to see added to this email alert, please email maureen_mcdonough@harvard.edu.